期刊文献+
共找到420篇文章
< 1 2 21 >
每页显示 20 50 100
Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease:A review of efficacy,safety,and outcomes
1
作者 Moiud Mohyeldin Ahmed S Abuelgasim Ahmed MG Mustafa 《World Journal of Cardiology》 2024年第7期397-401,共5页
Peripheral artery disease(PAD)is a common condition characterized by atherosclerosis in the peripheral arteries,associated with concomitant coronary and cerebrovascular diseases.Proprotein convertase subtilisin/kexin ... Peripheral artery disease(PAD)is a common condition characterized by atherosclerosis in the peripheral arteries,associated with concomitant coronary and cerebrovascular diseases.Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors are a class of drugs that have shown potential in hypercholesterolemic patients.This review focuses on the efficacy,safety,and clinical outcomes of PCSK9 inhibitors in PAD based on the literature indexed by PubMed.Trials such as FOURIER and ODYSSEY demonstrate the efficacy of evolocumab and alirocumab in reducing cardiovascular events,offering a potential treatment option for PAD patients.Safety evaluations from trials show few adverse events,most of which are injection-site reactions,indicating the overall safety profile of PCSK9 inhibitors.Clinical outcomes show a reduction in cardiovascular events,ischemic strokes,and major adverse limb events.However,despite these positive findings,PCSK9 inhibitors are still underutilized in clinical practice,possibly due to a lack of awareness among care providers and cost concerns.Further research is needed to establish the long-term effects and cost-effectiveness of PCSK9 inhibitors in PAD patients. 展开更多
关键词 Peripheral artery disease proprotein convertase subtilisin/kexin type 9 inhibitors Cardiovascular risk reduction Evolocumab Alirocumab Lipid-lowering therapy Major adverse limb events Clinical outcomes COST-EFFECTIVENESS Safety profile
暂未订购
Efficacy of Shoushen granule on adenosine triphosphate binding cassette transporter A1, proprotein convertase subtilisin/kexin type 9 and toll-like receptor 4/nuclear factor kappa-B signaling pathway in ApoE-knockout mice 被引量:6
2
作者 Li Shanshan Cao Hui +4 位作者 Shen Dingzhu Chen Chuan Xing Sanli Dou Fangfang Jia Qingling 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2019年第4期524-534,共11页
OBJECTIVE: To evaluate the efficacy of Shoushen granule, prepared with four Chinese medicinals, on the targeted regulation of adenosine triphosphate binding cassette transporter A1(ABCA1) through proprotein convertase... OBJECTIVE: To evaluate the efficacy of Shoushen granule, prepared with four Chinese medicinals, on the targeted regulation of adenosine triphosphate binding cassette transporter A1(ABCA1) through proprotein convertase subtilisin/kexin type 9(PCSK9) and toll-like receptor 4(TLR4)/nuclear factor kappa-B(NF-κB) signaling pathway to affect atherosclerosis(AS) in ApoE-knockout(ApoE-/-) mice.METHODS: ApoE-/-mice fed with a high-fat diet were used for AS modeling and divided into Model,Shoushen, and Atorvastatin groups. C57 BL/6 J mice at the same age and background strain were included in the Control group. Western blot and immunohistochemistry were used to measure ABCA1, PCSK9, TLR4, and NF-κB protein expression in mouse aortas. Enzyme-linked immuno sorbent assay was used to measure mouse serum tumor necrosis factor-α(TNF-α), interleukin-10(IL-10), monocyte chemoattractant protein 1(MCP-1), and intercellular cell adhesion molecule-1(ICAM-1) expression. Serum lipid profiles and histopathology were also assessed. Shoushen granule were composed of Heshouwu(Radix Polygoni Multiflori) 15 g, Gouqizi(Fructus Lycii) 15 g, Sheng shanzha(Raw Fructus Crataegus Pinnatifidae) 10 g, and Sanqi(Radix Notoginseng) 3 g.RESULTS: ApoE-/-mice fed with a high-fat diet had notable AS lesions, with reduced ABCA1 and IL-10 levels, elevated PCSK9, TLR4, NF-κB, TNF-α, MCP-1,and ICAM-1 expression, and increased total cholesterol(TC) and low density lipoprotein cholesterol(LDL-C) contents. With drug interventions, the areas of AS plaques were significantly reduced,the ABCA1 and IL-10 levels were increase, while the PCSK9, TLR4, NF-κB, TC, and LDL-C contents,and the TNF-α, MCP-1, and ICAM-1 expression were reduced.CONCLUSION: Shoushen granule effectively interfered with AS development by antagonizing the expression of key factors of the PCSK9 and TLR4/NF-κB signaling pathway to upregulate ABCA1 expression. 展开更多
关键词 Atherosclerosis ATP-BINDING cassette transporters proprotein convertases TOLL-LIKE receptor 4 NF-KAPPA B Shoushen GRANULE
原文传递
Hypercholesterolemia,low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 被引量:7
3
作者 Hong-mei Gu Da-wei Zhang 《The Journal of Biomedical Research》 CAS CSCD 2015年第5期356-361,共6页
Atherosclerotic cardiovascular disease is the main cause of mortality and morbidity in the world. Plasma levels of low density lipoprotein cholesterol (LDL-C) are positively correlated with the risk of atheroscleros... Atherosclerotic cardiovascular disease is the main cause of mortality and morbidity in the world. Plasma levels of low density lipoprotein cholesterol (LDL-C) are positively correlated with the risk of atherosclerosis. High plasma LDL concentrations in patients with hypercholesterolemia lead to build-up of LDL in the inner walls of the arteries, which becomes oxidized and promotes the formation of foam cells, consequently initiating atherosclerosis. Plasma LDL is mainly cleared through the LDL receptor (LDLR) pathway. Mutations in the LDLR cause familiar hyperch- olesterolemia and increase the risk of premature coronary heart disease. The expression of LDLR is regulated at the transcriptional level via the sterol regulatory element binding protein 2 (SREBP-2) and at the posttranslational levels mainly through proprotein convertase subtilisin/kexin-type 9 (PCSK9) and inducible degrader of the LDLR (IDOL). In this review, we summarize the latest advances in the studies of PCSK9. 展开更多
关键词 HYPERCHOLESTEROLEMIA low density lipoprotein receptor STATIN ATHEROSCLEROSIS proprotein convertasesubtilisin/kexin -type 9
暂未订购
Proprotein convertase 1/3-mediated down-regulation of brain-derived neurotrophic factor in cortical neurons induced by oxygen-glucose deprivation 被引量:3
4
作者 Xiang-Yang Zhang Feng Liu +2 位作者 Yan Chen Wei-Chun Guo Zhao-Hui Zhang 《Neural Regeneration Research》 SCIE CAS CSCD 2020年第6期1066-1070,共5页
Brain-derived neurotrophic factor(BDNF)has robust effects on synaptogenesis,neuronal differentiation and synaptic transmission and plasticity.The maturation of BDNF is a complex process.Proprotein convertase 1/3(PC1/3... Brain-derived neurotrophic factor(BDNF)has robust effects on synaptogenesis,neuronal differentiation and synaptic transmission and plasticity.The maturation of BDNF is a complex process.Proprotein convertase 1/3(PC1/3)has a key role in the cleavage of protein precursors that are directed to regulated secretory pathways;however,it is not clear whether PC1/3 mediates the change in BDNF levels caused by ischemia.To clarify the role of PC1/3 in BDNF maturation in ischemic cortical neurons,primary cortical neurons from fetal rats were cultured in a humidified environment of 95%N_2 and 5%CO_2 in a glucose-free Dulbecco's modified Eagle's medium at 37℃for3 hours.Enzyme-linked immunosorbent assays and western blotting showed that after oxygen-glucose deprivation,the secreted and intracellular levels of BDNF were significantly reduced and the intracellular level of PC1/3 was decreased.Transient transfection of cortical neurons with a PC1/3 overexpression plasmid followed by oxygen-glucose deprivation resulted in increased PC1/3 levels and increased BDNF levels.When levels of the BDNF precursor protein were reduced,the concentration of BDNF in the culture medium was increased.These results indicate that PC 1/3 cleavage of BDNF is critical for the conversion of pro-BDNF in rat cortical neurons during ischemia.The study was approved by the Animal Ethics Committee of Wuhan University School of Basic Medical Sciences. 展开更多
关键词 cortical neuron ischemia NEUROTROPHIN oxygen-glucose deprivation precursor protein of BRAIN-DERIVED NEUROTROPHIC factor proprotein CONVERTASE proprotein CONVERTASE 1/3
暂未订购
Proprotein convertase 1 mRNA and protein expression in ischemic rat cortex after reperfusion 被引量:2
5
作者 Shuqin Zhan An Zhou +1 位作者 Jingquan Lan Tao Yang 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第4期295-299,共5页
Proprotein convertase 1 (PC1) is a member of the family of proprotein convertases (PCs), which are the processing enzymes of neuropeptides. Previous studies have addressed PC1 effects with regard to the neuroendoc... Proprotein convertase 1 (PC1) is a member of the family of proprotein convertases (PCs), which are the processing enzymes of neuropeptides. Previous studies have addressed PC1 effects with regard to the neuroendocrine system. In this study, the developing changes of PC1 mRNA and PC1 protein in rat cortices after transient focal cerebral ischemia were investigated by fluorescent double labeling (both in situ hybridization and immunocytochemistry) using a transient focal cerebral ischemia model in rats. The results were compared with those of sham-operated rat cortices. Both the mRNA and protein levels of PC1 in ischemic cortices decreased gradually at 4, 8, and 16 hours of reperfusion after 100 minutes of middle cerebral artery occlusion. After 24 hours of reperfusion, enhanced intensities of signals for PC1 protein were observed, while signals for PC1 mRNA remained low. These results suggest that transient focal cerebral ischemia influences PC1 mRNA and protein expression in cortices of ischemic rats. Thus, PC1 is regulated by ischemic stress. 展开更多
关键词 cerebral ischemia proprotein convertase 1 CORTEX rats
在线阅读 下载PDF
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver 被引量:7
6
作者 Muhammad Shafiq Timothy Walmann +2 位作者 Venkat Nutalapati Cheryl Gibson Yousaf Zafar 《World Journal of Hepatology》 2020年第12期1258-1266,共9页
BACKGROUND Many studies have investigated the progression of nonalcoholic fatty liver disease(NAFLD)and its predisposing risk factors,but the conclusions from these studies have been conflicting.More challenging is th... BACKGROUND Many studies have investigated the progression of nonalcoholic fatty liver disease(NAFLD)and its predisposing risk factors,but the conclusions from these studies have been conflicting.More challenging is the fact that no effective treatment is currently available for NAFLD.AIM To determine the effects of proprotein convertase subtilisin/kexin type-9(PCSK9)inhibitors on fatty infiltration of the liver.METHODS This retrospective,chart review-based study was conducted on patients,18-yearold and above,who were currently on PCSK9 inhibitor drug therapy.Patients were excluded from the study according to missing pre-or post-treatment imaging or laboratory values,presence of cirrhosis or rhabdomyolysis,or development of acute liver injury during the PCSK9 inhibitor treatment period;the latter being due to false elevation of liver function markers,alanine aminotransferase(ALT)and aspartate aminotransferase(AST).Radiographic improvement was assessed by a single radiologist,who read both the pre-and post-treatment images to minimize reading bias.Fatty infiltration of the liver was also assessed by changes in ALT and AST,with pre-and post-treatment levels compared by paired t-test(alpha criterion:0.05).RESULTS Of the 29 patients included in the study,8 were male(27.6%)and 21 were female(72.4%).Essential hypertension was present in 25(86.2%)of the patients,diabetes mellitus in 18(62.1%)and obesity in 15(51.7%).In all,patients were on PCSK9 inhibitors for a mean duration of 23.69±11.18 mo until the most recent ALT and AST measures were obtained.Of the 11 patients who received the radiologic diagnosis of hepatic steatosis,8(72.73%)achieved complete radiologic resolution upon use of PCSK9 inhibitors(mean duration of 17.6 mo).On average,the ALT level(IU/L)decreased from 21.83±11.89 at pretreatment to 17.69±8.00 at posttreatment(2-tailed P=0.042)and AST level(IU/L)decreased from 22.48±9.00 pretreatment to 20.59±5.47 post-treatment(2-tailed P=0.201).CONCLUSION PCSK9 inhibitors can slow down or even completely resolve NAFLD. 展开更多
关键词 proprotein convertase subtilisin/kexin type-9 inhibitor Fatty liver Nonalcoholic fatty liver disease Alanine aminotransferase Aspartate aminotransferase IMAGING
暂未订购
The proprotein convertase subtilisin/kexin type 9 geneE670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations 被引量:9
7
作者 Lynn Htet Aung,YIN Rui-xing,MIAO Lin,HU Xi-jiang, YAN Ting-ting,CAO Xiao-li,WU Dong-feng,LI Qing,PAN Shang-ling,WU Jin-zhen (Department of Cardiology,Institute of Cardiovascular Diseases, The First Affiliated Hospital,Guangxi Medical University, Nanning 530021,China) 《岭南心血管病杂志》 2011年第S1期162-162,共1页
Background The association of E670G polymorphism in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and serum lipid profiles is inconsistent in dif- ferent ethnic groups.Bai Ku Yao is a special subgroup... Background The association of E670G polymorphism in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and serum lipid profiles is inconsistent in dif- ferent ethnic groups.Bai Ku Yao is a special subgroup of the Yao minority in China.The present study was undertaken association of PCSK9 E670G polymorphism and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.Methods A total of 649 subjects of Bai Ku Yao and 646 participants of Han Chinese were randomly selected from our previous stratified randomized cluster samples.Genotyping of the PCSK9 E670G polymorphism was performed by polymerase chain reaction and restriction fragment length polymorphism combined with gel electrophoresis,and then confirmed by direct sequencing. Results The levels of serum total cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C) and apolipoprotein(Apo) AI were lower in Bai Ku Yao than in Han(P【0.01 for all).The frequency of A and G alleles was 98.00%and 2.00%in Bai Ku Yao,and 95.20%and 4.80%in Han(P【0.01);respectively. The frequency of AA,AG and GG genotypes was 95.99%,4.01%and 0%in Bai Ku Yao,and 91.02%, 8.36%and 0.62%in Han(P【0.01);respectively.There were also significant differences in the genotypic and allelic frequencies between n and the ratio of ApoAI to ApoB in Han Chinese but not in Bai Ku Yao were different between the AA and AG/GG genotypes(P【0.05 for all).The G allele carriers had higher serum HDL-C and higher ApoAI to ApoB ratio than the G allele noncarriers.When serum lipid parameters in Han were analyzed according to sex,the G allele carriers had higher serum HDL and ApoAI levels in males (P【0.05),and lower ApoB level and higher ApoAI to ApoB ratio in females(P【0.05 for all).Multiple linear regression analysis showed that serum HDL-C levels were correlated with genotypes in both ethnic groups(P【0.05 each).Serum lipid parameters were also correlated with sex,age,body massindex,alcohol consumption,cigarette smoking,and blood pressure in both ethnic groups(P【0.05-0.001).Conclusions These results suggest that the PCSK9 E670G polymorphism is mainly associated with some serum lipid parameters in the Han population,both gender show different relations to different serum lipid parameters.The G allele carriers might have higher serum lipid profiles than the G allele noncarriers. ormal LDL-C(≤3.20 mmol/L) and high LDL-C subgroups (】 3.20 mmol/L,P【0.01;respectively) in Bai Ku Yao, and between normal ApoB(≤1.14 g/L) and high ApoB subgroups(】 1.14 g/L,P 【 0.01;respectively) in Han. 展开更多
关键词 ApoB The proprotein convertase subtilisin/kexin type 9 geneE670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations TYPE
暂未订购
Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization:A case report 被引量:1
8
作者 Liu Yang Yan-Yan Xiao +5 位作者 Liang Shao Chang-Sheng Ouyang Yao Hu Bin Li Li-Feng Lei Hong Wang 《World Journal of Clinical Cases》 SCIE 2022年第19期6728-6735,共8页
BACKGROUND Familial hypercholesterolemia(FH)is an autosomal dominant disorder that is characterized by severely increased low-density lipoprotein(LDL)cholesterol levels.At the same time,elevated LDL levels accelerated... BACKGROUND Familial hypercholesterolemia(FH)is an autosomal dominant disorder that is characterized by severely increased low-density lipoprotein(LDL)cholesterol levels.At the same time,elevated LDL levels accelerated the development of coronary heart disease.Several classes of drugs are currently in use to treat FH.Proprotein convertase subtilisin/kexin type 9 inhibitor(PCSK9i)is novel one of these.CASE SUMMARY This manuscript reports a case of FH that responded modestly after treatment with PCSK9i and statin drugs.Of even more concern is that the patient frequently admitted to the hospital during a 12-year follow-up period.Subsequently,we identified a heterozygous mutation,1448G>A(W483X)of the LDL receptor(LDLR)in this patient.The serum levels of PCSK9(proprotein convertase subtilisin/kexin type 9)in the patient was 71.30±26.66 ng/mL,which is close the average level reported in the literature.This LDLR mutation affects LDLR metabolism or structure,which may make it unsuitable for use of PCSK9i.CONCLUSION Our outcome demonstrates that LDLR-W483X represents a partial loss-of-function LDLR and may contribute to PCSK9i ineffective. In the meanwhile, additional measures aretherefore required (particularly with gene sequencing or change the treatment plan) must beinitiated as early as possible. Genetic testing for clinically challenging cases who do not respond toPCSK9i therapy is very helpful. 展开更多
关键词 Coronary artery disease Familial hypercholesterolemia Low-density lipoprotein receptor mutation Non response proprotein convertase subtilisin/kexin type 9 inhibitor
暂未订购
Dynamic changes in proprotein convertase 2 activity in cortical neurons after ischemia/reperfusion and oxygen-glucose deprivation
9
作者 Shuqin Zhan An Zhou +1 位作者 Chelsea Piper Tao Yang 《Neural Regeneration Research》 SCIE CAS CSCD 2013年第1期83-89,共7页
In this study, a rat model of transient focal cerebral ischemia was established by performing 100 minutes of middle cerebral artery occlusion, and an in vitro model of experimental oxygen-glucose deprivation using cul... In this study, a rat model of transient focal cerebral ischemia was established by performing 100 minutes of middle cerebral artery occlusion, and an in vitro model of experimental oxygen-glucose deprivation using cultured rat cortical neurons was established. Proprotein convertase 2 activity gradually decreased in the ischemic cortex with increasing duration of reperfusion. In cultured rat cortical neurons, the number of terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate-biotin nick end labeling-positive neurons significantly increased and proprotein convertase 2 activity also decreased gradually with increasing duration of oxygen-glucose deprivation. These experimental findings indicate that proprotein convertase 2 activity decreases in ischemic rat cortex after reperfusion, as well as in cultured rat cortical neurons after oxygen-glucose deprivation. These changes in enzyme activity may play an important pathological role in brain injury. 展开更多
关键词 neural regeneration brain injury proprotein convertase 2 cortex neuron cerebralischemia/reperfusion oxygen-glucose deprivation in vivo study in vitro study grants-supportedpaper photographs-containing paper NEUROREGENERATION
暂未订购
Changes in proprotein convertase subtilisin/kexin type 9 mRNA expression in rat cortex after cerebral ischemia
10
作者 Shuqin Zhan An Zhou +1 位作者 Jingquan Lan Tao Yang 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第13期995-999,共5页
Oxidized low density lipoprotein is a risk factor for cerebrovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can increase the level of low density lipoprotein. Therefore, this study assumed t... Oxidized low density lipoprotein is a risk factor for cerebrovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can increase the level of low density lipoprotein. Therefore, this study assumed that PCSK9 plays important roles in ischemic cerebrovascular disease. The present study established transient focal cerebral ischemia models after 100 minutes of middle cerebral artery occlusion. In situ hybridization demonstrated that PCSK9 mRNA expression increased gradually with prolonged reperfusion time in ischemic cortices. This indicated that transient focal cerebral ischemia upregulated PCSK9 mRNA expression in ischemic cortices. 展开更多
关键词 cerebral ischemia proprotein convertase subtilisin/kexin type 9 mRNA CORTEX neural regeneration
在线阅读 下载PDF
PCSK9抑制剂应用于治疗缺血性卒中的研究进展 被引量:1
11
作者 王翠翠 王舒 肇丽梅 《中国新药与临床杂志》 北大核心 2025年第3期189-194,共6页
前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂单独或联合他汀类药物治疗的基础上大幅度降低低密度脂蛋白胆固醇(LDL-C)水平,并且有改善内皮细胞功能、减轻氧化应激和血管炎症、稳定动脉粥样硬化斑块、减少血小板聚集的作用,可改善心血管疾病... 前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂单独或联合他汀类药物治疗的基础上大幅度降低低密度脂蛋白胆固醇(LDL-C)水平,并且有改善内皮细胞功能、减轻氧化应激和血管炎症、稳定动脉粥样硬化斑块、减少血小板聚集的作用,可改善心血管疾病的预后,降低缺血性卒中的发生率,且具有良好的安全性。PCSK9抑制剂通过阻断PCSK9与LDL受体的结合,减少肝脏LDL受体的降解,进而降低血清中LDL-C水平。临床研究显示,PCSK9抑制剂降低LDL-C的效果具有持续性,并表现出良好的安全性和耐受性,与降低缺血性卒中风险相关,且不增加出血性卒中风险。 展开更多
关键词 前蛋白转化酶枯草溶菌素9抑制剂 缺血性卒中 阿利西尤单抗 依洛尤单抗 英克司兰
原文传递
血清NF-kB、PCSK9联合幽门螺旋杆菌检测对早期胃癌的诊断价值
12
作者 贾纯亮 梁磊 +4 位作者 李翰嵩 王剑 张磊 李青科 姚远 《中国实验诊断学》 2025年第11期1307-1311,共5页
目的 探讨血清核转录因子-kB(NF-kB)、前蛋白转化酶枯草杆菌蛋白酶9型(PCSK9)联合幽门螺旋杆菌检测对早期胃癌的诊断价值。方法 选取2022年5月至2025年1月在唐山市人民医院检查疑似胃癌患者106例,根据病理检测结果分为胃炎组(n=61)和胃... 目的 探讨血清核转录因子-kB(NF-kB)、前蛋白转化酶枯草杆菌蛋白酶9型(PCSK9)联合幽门螺旋杆菌检测对早期胃癌的诊断价值。方法 选取2022年5月至2025年1月在唐山市人民医院检查疑似胃癌患者106例,根据病理检测结果分为胃炎组(n=61)和胃癌组(n=45),均进行血清NF-kB、PCSK9及幽门螺旋杆菌检测,收集分析一般临床资料,Logistic回归分析早期胃癌影响因素,绘制受试者工作特征(ROC)曲线,分析血清NF-kB、PCSK9对早期胃癌的诊断价值,Kappa一致性检验分析幽门螺旋杆菌检测及三者联合检测与病理结果的一致性。结果 胃癌组的血清NF-kB、PCSK9水平较胃炎组显著升高(P<0.05),幽门螺旋杆菌检测阳性率高于胃炎组(P<0.05);NF-kB、PCSK9水平升高,幽门螺旋杆菌阳性均为影响胃癌发生的危险因素;幽门螺旋杆菌检测与金标准的Kappa为0.645,具有高度一致性(P<0.05),三者与金标准的Kappa为0.807,具有极高一致性(P<0.05);三者联合诊断早期胃癌的特异度、阳性预测值及准确度显著高于NF-kB、PCSK9、幽门螺旋杆菌单独检测(P<0.05)。结论 血清NF-kB、PCSK9在早期胃癌患者中表达升高,血清NF-kB、PCSK9联合幽门螺旋杆菌检测对早期胃癌具有一定诊断价值。 展开更多
关键词 核转录因子-KB 前蛋白转化酶枯草杆菌蛋白酶9型 幽门螺旋杆菌检测 早期胃癌 诊断
暂未订购
经皮冠状动脉介入治疗患者依洛尤单抗治疗后不同血脂水平与预后的关系
13
作者 郑泽 袁鹏 +3 位作者 但汉威 井浣雨 李世英 史雨晨 《中国介入心脏病学杂志》 2025年第10期553-560,共8页
目的探讨不同低密度脂蛋白胆固醇(LDL-C)水平与经皮冠状动脉介入治疗(PCI)术后患者应用前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂强化降脂治疗预后的临床相关性,为个体化降脂目标的制订提供循证依据。方法选择首都医科大学附... 目的探讨不同低密度脂蛋白胆固醇(LDL-C)水平与经皮冠状动脉介入治疗(PCI)术后患者应用前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂强化降脂治疗预后的临床相关性,为个体化降脂目标的制订提供循证依据。方法选择首都医科大学附属北京安贞医院2020年1月至2023年6月择期PCI,并且增加依洛尤单抗进行降脂治疗的患者,根据术后3~6个月血脂复查结果,根据LDL-C水平将患者分为5组:LDL-C<0.5 mmol/L组,0.5~1.0 mmol/L组,1.0~1.4 mmol/L组,1.4~1.8 mmol/L组,≥1.8 mmol/L组。所有患者进行了至少12个月的随访,记录临床情况和主要不良心血管事件(MACE)。结果首先纳入1106例PCI患者,行倾向性评分匹配并排除失访患者得到550例(每组110例)。随访12个月MACE共发生58例(10.5%),其发生率随LDL-C水平呈阶梯上升。多因素Cox回归分析(调整年龄、性别、糖尿病、高血压病、基线LDL-C水平、复查LDL-C水平、估算的肾小球滤过率和左心室射血分数)显示,0.5~1.0 mmol/L组,1.0~1.4 mmol/L组,1.4~1.8 mmol/L组,≥1.8 mmol/L组与LDL-C<0.5 mmol/L组相比,MACE风险比分别为(HR1.810,95%CI 0.507~6.454,P=0.361;HR 3.036,95%CI 0.945~9.749,P=0.062;HR 5.228,95%CI1.737~15.735,P=0.003;HR 7.708,95%CI 2.633~22.56,P<0.001)。限制性立方样条模型显示LDL-C与MACE呈显著非线性正相关(P-overall≤0.001,P-non-linear=0.008);年龄、性别、高血压病及糖尿病各亚组HR方向一致,交互作用(均P>0.05)。各组出血事件、肌酐升高与肝功能异常发生率比较,差异均无统计学意义(均P>0.05)。结论PCI术后应用PCSK9抑制剂治疗的患者中,LDL-C水平与MACE风险呈显著的正相关,未观察到不同LDL-C水平与出血等不良事件风险的相关性。 展开更多
关键词 经皮冠状动脉介入治疗 前蛋白转化酶枯草杆菌蛋白酶/kexin 9型 主要不良心血管事件 出血事件
暂未订购
H型高血压病人血清可溶性肿瘤发生抑制蛋白2、前蛋白转化酶枯草溶菌素9水平与心功能、预后的关系
14
作者 周婷婷 柏业军 +2 位作者 刘敏 李志刚 刘玲玲 《中西医结合心脑血管病杂志》 2025年第7期1068-1072,共5页
目的:分析H型高血压病人血清可溶性肿瘤发生抑制蛋白2(sST2)、前蛋白转化酶枯草溶菌素9(PCSK9)水平与心功能、预后的关系。方法:选取徐州市中心医院2021年1月—2022年3月收治的H型高血压病人124例为H型高血压组,同期非H型高血压病人87... 目的:分析H型高血压病人血清可溶性肿瘤发生抑制蛋白2(sST2)、前蛋白转化酶枯草溶菌素9(PCSK9)水平与心功能、预后的关系。方法:选取徐州市中心医院2021年1月—2022年3月收治的H型高血压病人124例为H型高血压组,同期非H型高血压病人87例为非H型高血压组,同期体检健康者100名为对照组。根据H型高血压病人是否发生心血管事件分为预后良好组和预后不良组。酶联免疫吸附法测定血清sST2、PCSK9水平。分析血清sST2、PCSK9水平与心功能指标的相关性;受试者工作特征(ROC)曲线分析血清sST2、PCSK9水平对H型高血压病人预后的预测价值;Logistic回归分析H型高血压预后不良的影响因素。结果:H型高血压组血清sST2、PCSK9水平高于非H型高血压组、对照组(P<0.05),非H型高血压组血清sST2、PCSK9水平高于对照组(P<0.05)。预后良好组血清sST2、PCSK9水平明显低于预后不良组(P<0.05);H型高血压病人同型半胱氨酸、低密度脂蛋白胆固醇(LDL-C)、C反应蛋白(CRP)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室质量指数均明显高于非H型高血压组(P<0.05),高密度脂蛋白胆固醇(HDL-C)、左室射血分数、心脏指数明显低于非H型高血压组(P<0.05)。H型高血压病人血清sST2与PCSK9水平呈正相关(r=0.337,P<0.05),血清sST2、PCSK9水平与左室射血分数、心脏指数呈负相关(P<0.05),与LVEDD、LVESD、左室质量指数、同型半胱氨酸、LDL-C、CRP呈正相关(P<0.05)。血清sST2、PCSK9联合检测评估H型高血压病人预后不良的ROC曲线下面积(AUC)高于sST2、PCSK9单独检测(Z_(sST2-联合)=3.074,P=0.002;Z_(PCSK9-联合)=2.176,P=0.030)。sST2、PCSK9、同型半胱氨酸、LDL-C、CRP为H型高血压病人预后不良的影响因素(P<0.05)。结论:H型高血压病人血清sST2、PCSK9水平与心功能、预后密切相关。 展开更多
关键词 H型高血压 可溶性肿瘤发生抑制蛋白2 前蛋白转化酶枯草溶菌素9 心功能 预后
暂未订购
2024年欧洲心脏病学会血脂热点速递
15
作者 黄进宇 《心电与循环》 2025年第2期113-117,125,共6页
2024年8月30日至9月2日在英国伦敦召开的2024年欧洲心脏病学会(ESC 2024)会议上,众多研究者发布了针对血脂异常的最新探索结果,内容涵盖血脂管理现状、最新降脂理念更新、新靶点及新型降脂药物研发及临床实践优化等方面。本文从新药物... 2024年8月30日至9月2日在英国伦敦召开的2024年欧洲心脏病学会(ESC 2024)会议上,众多研究者发布了针对血脂异常的最新探索结果,内容涵盖血脂管理现状、最新降脂理念更新、新靶点及新型降脂药物研发及临床实践优化等方面。本文从新药物和治疗方法、脂蛋白(a)降低疗法、前蛋白转化酶枯草溶菌素9、英克司兰、个体化治疗等方面对ESC 2024会议的关键内容作一述评。 展开更多
关键词 血脂异常 前蛋白转化酶枯草溶菌素9 英克司兰 脂蛋白(a)
暂未订购
The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms
16
作者 Zehua He Mingtian Lu +7 位作者 Zhejing Ding Zhengwei Chen Tianyang Guan Zhongliang Li Cheng Zhou Haiquan Tao Guangsen Cheng Yu Liu 《American Journal of Molecular Biology》 2025年第1期110-122,共13页
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell su... Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell surface pathways, consequently elevating serum LDL-C levels. PCSK9 is implicated in various processes such as lipid metabolism, atherosclerosis, oxidative stress, inflammatory responses, thrombosis, and apoptosis. It is closely linked to ischemic stroke through its role in inducing and advancing atherosclerosis. PCSK9 inhibitors play a useful role in both acute and secondary prevention of ischemic stroke and can reduce the risk of ischemic stroke. This review examines the influence of PCSK9 on the risk factors associated with ischemic stroke and explores its potential mechanisms, and briefly describes the application of PCSK9 inhibitors in ischemic stroke. 展开更多
关键词 proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Ischemic Stroke ATHEROSCLEROSIS INFLAMMATION
暂未订购
多囊卵巢综合征患者血清前蛋白转化酶枯草溶菌素9表达水平与糖脂代谢及胰岛素抵抗的相关性研究
17
作者 郭晓莉 惠晶 惠慧 《现代检验医学杂志》 2025年第2期156-159,共4页
目的探讨血清前蛋白转化酶枯草溶菌素9(PCSK9)与多囊卵巢综合征(PCOS)患者糖脂代谢和胰岛素抵抗(IR)的关系。方法选取2019年6月~2021年8月延安市人民医院收治的初诊PCOS患者154例作为PCOS组,采用稳态模型计算患者的胰岛素抵抗指数(HOMA-... 目的探讨血清前蛋白转化酶枯草溶菌素9(PCSK9)与多囊卵巢综合征(PCOS)患者糖脂代谢和胰岛素抵抗(IR)的关系。方法选取2019年6月~2021年8月延安市人民医院收治的初诊PCOS患者154例作为PCOS组,采用稳态模型计算患者的胰岛素抵抗指数(HOMA-IR),将HOMA-IR<2.69者纳入到非IR组(n=62),HOMA-IR≥2.69者纳入到IR组(n=92)。另选取同期延安市人民医院体检结果为正常的健康志愿者50例作为对照组。采用酶联免疫试剂盒检测血清PCSK9的水平。比较所有研究对象的性激素指标以及糖脂代谢指标差异。Pearson相关分析PCOS患者血清PCSK9与糖脂代谢指标及性激素指标的关系;多因素Logistics回归分析PCOS患者并发IR的影响因素。结果PCOS组血清PCSK9(292.57±42.31ng/ml)高于对照组(226.94±20.18ng/ml),差异具有统计学意义(t=10.379,P<0.001)。IR组患者血清PCSK9(324.51±50.33 ng/m l)高于非IR组(245.18±40.16 ng/ml),差异具有统计学意义(t=10.379,P<0.001)。Pearson分析显示,PCOS患者血清PCSK9与LH,空腹血糖、空腹胰岛素、HOMA-IR,LDL-C,TC和TG均呈正相关(r=0.302~0.684,均P<0.05)。经多因素Logsitic回归分析显示,空腹血糖、空腹胰岛素和血清PCSK9均是PCOS患者并发IR的影响因素(Wald χ^(2)=8.501,8.024,7.886,均P<0.05)。结论PCSK9在PCOS患者血清中呈异常高表达,且其表达水平与患者的糖脂代谢以及IR情况密切相关。 展开更多
关键词 多囊卵巢综合征 前蛋白转化酶枯草溶菌素9 胰岛素抵抗 糖脂代谢
暂未订购
前蛋白转化酶枯草杆菌蛋白酶/溶菌素9抑制剂治疗高胆固醇血症的经济性评价系统综述 被引量:1
18
作者 孙凌垚 王文珊 +4 位作者 王心茹 袁方哲 顾钰祺 谭玉洁 田磊 《中国新药杂志》 北大核心 2025年第7期778-784,共7页
目的:探究前蛋白转化酶枯草杆菌蛋白酶/溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂药物经济性评价的方法。方法:检索从建库至2024年1月15日PubMed,Embase,Scopus,Cochrane Library和Web of science数据库中有... 目的:探究前蛋白转化酶枯草杆菌蛋白酶/溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂药物经济性评价的方法。方法:检索从建库至2024年1月15日PubMed,Embase,Scopus,Cochrane Library和Web of science数据库中有关PCSK9抑制剂经济学研究的文献,并使用2022年版综合卫生经济评价报告标准(Consolidated Health Economic Evaluation Reporting Standards,CHEERS)对纳入的文献进行评估。结果:30篇关于PCSK9抑制剂药物治疗心血管疾病的经济学评价研究中27篇采用了模型法进行经济学评价,主要使用马尔可夫模型,涵盖了多个研究时限和健康状态数量。23篇文献通过低密度脂蛋白胆固醇(low-density lipoproteins-cholesterol,LDL-C)水平降低进行外推来评估药效,23篇文献未考虑药物的不良反应。结论:现有文献主要通过马尔可夫模型对药物的经济性进行评价,在药物效果指标的选择、药物不良反应是否纳入分析等方面存在局限性。 展开更多
关键词 前蛋白转化酶枯草杆菌蛋白酶/溶菌素9抑制剂 经济性 方法学 系统综述
原文传递
PI联合CitH3及PCSK9在脓毒性休克患者预后评估中的价值 被引量:1
19
作者 徐丽娜 任思思 +1 位作者 李焱 李国峰 《广东医学》 2025年第2期256-260,共5页
目的探究外周灌注指数(peripheral perfusion index,PI)联合血清瓜氨酸组蛋白H3(serum citrullinated histone 3,CitH3)、前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)对脓毒性休克患者预后评估的作... 目的探究外周灌注指数(peripheral perfusion index,PI)联合血清瓜氨酸组蛋白H3(serum citrullinated histone 3,CitH3)、前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)对脓毒性休克患者预后评估的作用。方法选择于2022年3月至2024年3月天津市北辰医院就诊的脓毒性休克患者120例作为观察对象。根据28 d内死亡情况分为死亡组(n=43)和生存组(n=77)。Pearson法分析PI与血清CitH3、PCSK9的相关性。脓毒性休克患者预后的影响因素采用多因素logistic回归分析。绘制受试者工作特征(ROC)曲线分析脓毒性休克患者死亡的预测价值。结果死亡组和生存组序贯器官衰竭量表(SOFA)评分[(7.86±1.78)分vs.(5.91±1.39)分]、急性生理与慢性健康评分(APACHE-Ⅱ)评分[(21.83±3.52)分vs.(19.13±2.81)分]、血清肿瘤坏死因子-α(TNF-α)水平[(159.87±23.63)μg/L vs.(124.56±19.85)μg/L]比较差异有统计学意义(P<0.05)。与生存组比较,死亡组血清CitH3、PCSK9[(64.37±21.75)pg/mL vs.(36.28±10.09)pg/mL,(489.25±93.17)ng/mL vs.(338.19±78.43)ng/mL]水平较高,PI较低[0.98±0.29 vs.1.54±0.31](P<0.05)。PI与血清CitH3、PCSK9呈负相关(r=-0.499、-0.516,P<0.001),血清CitH3与PCSK9呈正相关(r=0.504,P<0.001)。多因素logistic回归分析得知,PI为影响脓毒症休克患者死亡的保护因素,CitH3、PCSK9、TNF-α为危险因素(P<0.05)。PI预测脓毒性休克患者死亡的AUC为0.831,血清CitH3预测脓毒性休克患者死亡的AUC为0.830,血清PCSK9预测脓毒性休克患者死亡的AUC为0.854,三者联合预测脓毒性休克患者死亡的AUC为0.957,三者联合优于各自单独预测(P<0.05)。结论PI降低,血清CitH3,PCSK9水平升高与脓毒性休克患者预后相关,三者联合对脓毒性休克患者预后具有较高的预测价值。 展开更多
关键词 外周灌注指数 瓜氨酸组蛋白H3 前蛋白转化酶枯草溶菌素9 脓毒性休克 预后
暂未订购
依洛尤单抗导致闭角型青光眼急性发作一例报道
20
作者 吴曼 罗樱樱 纪立农 《中国糖尿病杂志》 北大核心 2025年第10期789-792,共4页
依洛尤单抗是降低LDL-C水平和心血管疾病全因死亡率的降脂药物,临床应用时较少出现眼部不良反应。本文报告1例原发性闭角型青光眼患者,使用前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂依洛尤单抗降脂治疗3次后,出现左眼肿痛及视物模糊。眼... 依洛尤单抗是降低LDL-C水平和心血管疾病全因死亡率的降脂药物,临床应用时较少出现眼部不良反应。本文报告1例原发性闭角型青光眼患者,使用前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂依洛尤单抗降脂治疗3次后,出现左眼肿痛及视物模糊。眼科检查显示,左眼眼压明显升高,考虑闭角型青光眼急性发作。经过治疗后眼压降至正常水平。本文探讨该病例并复习相关文献,提示临床使用PCSK9抑制剂时,应密切监测患者眼部状况,尤其是有青光眼危险因素的患者。 展开更多
关键词 前蛋白转化酶枯草溶菌素9型抑制剂 青光眼 眼压 血脂
原文传递
上一页 1 2 21 下一页 到第
使用帮助 返回顶部